HAO Yu-pei,CUI Yan-yu,ZHAO Ruo-nan,et al.Research Progress in Mechanism of Chinese Materia Medica in the Treatment of Uterine Leiomyoma[J].Chinese Journal of Library and Information Science for Traditional Chinese Medicine,2021,45(4):69-73.[doi:10.3969/j.issn.2095-5707.2021.04.017]
中药治疗子宫肌瘤的作用机制研究进展
- Title:
- Research Progress in Mechanism of Chinese Materia Medica in the Treatment of Uterine Leiomyoma
- 文章编号:
- 2095-5707(2021)04-0069-05
- Keywords:
- uterine leiomyoma; Chinese materia medica; mechanism; review
- 分类号:
- R273
- 文献标志码:
- A
- 摘要:
- 子宫肌瘤是女性生殖系统常见的良性肿瘤之一，其治疗方法包括手术治疗、药物治疗两大类。中医认为子宫肌瘤的核心病机是正虚血瘀，针对该病机运用中药治疗取得了显著效果。本文总结近10年治疗子宫肌瘤的单味中药、药对及成方的作用机制，包括抑制肿瘤细胞增殖、促进肿瘤细胞凋亡、改善血液微循环和血黏稠度、降低激素水平等，为临床治疗子宫肌瘤提供参考依据。
- Abstract:
- Uterine leiomyoma is a benign tumor which often occurs in female’s genitalia. Its treatment includes surgical treatment and drug treatment. TCM believes that the core pathogenesis of uterine leiomyoma is deficiency of the vital essestial and blood stasis, and the use of Chinese materia medica to treat the pathogenesis has achieved remarkable results. This article summarized the single Chinese materia medica, medicinal pairs and Chinese patent medicines used in the treatment of uterine leiomyoma in the past 10 years, and concluded their mechanism, including inhibiting tumor cell proliferation, promoting tumor cell apoptosis, improving blood microcirculation and blood viscosity, reducing hormone level, in order to provide reference for clinical treatment of uterine leiomyoma.
参考文献/References:
[1] 陈红菊,尹伶.子宫肌瘤病因学的研究进展[J].实用预防医学,2012,19(6):959-961.
[2] 王芳芳,张晓甦.子宫肌瘤病因病机理论探讨[J].吉林中医药,2010,30(11):921-923.
[3] 杨卓,孟宪红.清热养血法治疗围绝经期子宫肌瘤38例临床观察[J].中国乡村医药,2012,19(8):47-48.
[4] 赵欣,李丹丹,刘淑香.黄连素对子宫肌瘤大鼠模型血液黏度、子宫系数、平滑肌厚度和炎性细胞浸润的影响[J].临床和实验医学杂志,2020,19(6):589-592.
[5] 黄亚哲,安爱平,陈建玲,等.黄连素对实验性子宫肌瘤大鼠的作用及相关机制[J].临床与病理杂志,2017,37(8):1565-1570.
[6] 魏新智,闵冬雨,王清华,等.赤芍组分SY-002抗雌孕激素诱导大鼠子宫肌瘤作用的研究[J].中华中医药学刊,2017,35(2):405-407,522.
[7] 陶晓倩,李娜,曹亮,等.桂枝茯苓胶囊中主要成分对人子宫肌瘤细胞增殖及小鼠离体子宫收缩活动的影响[J].中国实验方剂学杂志,2016,22(2):91-96.
[8] 王佳,梁葵香,刘艳妮,等.茯苓酸通过上调miR-133a影响子宫肌瘤细胞增殖凋亡及表皮生长因子的水平[J].中国免疫学杂志,2020,36(9):1069-1074.
[9] 于政,郑雪绒,赵亚宁,等.姜三七对子宫肌瘤大鼠子宫组织细胞凋亡及Bcl-2、Bax蛋白表达的影响[J].现代生物医学进展,2017,17(35):6921-6924,6991.
[10] 李文静,李雪岩,崔涛,等.莪术-三棱药对合煎液对大鼠子宫肌瘤的防治作用及机制研究[J].中国药房,2017,28(19):2609-2612.
[11] 付煜,徐秋霞,张黎,等.“三棱-莪术”组分配伍对子宫肌瘤大鼠下丘脑和垂体激素的影响[J].中药与临床,2020,11(2):31-36.
[12] 肖红妮,刘志杰.“三棱-莪术”组分配伍介导PI3K-AKT通路治疗大鼠子宫肌瘤的研究[J].世界中医药,2019,14(9):2267-2271.
[13] 宿树兰,薛萍,欧阳臻,等.蒲黄-五灵脂配伍前后效应成分变化及其抗血小板聚集和抗凝血酶活性评价[J].中国中药杂志,2015,40(16):3187-3192.
[14] 周卫,宿树兰,刘培,等.蒲黄-五灵脂药对不同提取物活血化瘀效应的比较研究[J].南京中医药大学学报,2010,26(3):211-213.
[15] 朱丽红,肖艳.大黄与?对药含药血清对胰岛素样生长因子-Ⅰ和表皮生长因子促进人子宫肌瘤细胞增殖的影响[J].中华中医药杂志,2012,27(5):1390-1393.
[16] 朱丽红,袁欢欢.大黄、?对药对雌孕激素负荷大鼠子宫肌瘤模型ERα、ERβ的影响[J].辽宁中医杂志,2011,38(11):2156-2158.
[17] 王亚松,李冬华,邹小丽,等.理冲汤对子宫肌瘤模型大鼠血清激素水平及组织病理改变的影响[J].现代中西医结合杂志,2012,21(5):475-477.
[18] 王晶.理冲汤可有效降低子宫肌瘤患者MMP-2、FSH等水平并改善临床症状[J].基因组学与应用生物学,2018,37(9):4042-4047.
[19] 王文娜,李冬华,刘宇,等.理冲汤对子宫肌瘤模型小鼠Th1/Th2平衡漂移的调控作用研究[J].医学研究杂志,2020,49(1):52-56.
[20] 朱丽娟,李冬华,张武芳,等.理冲汤对异种移植子宫肌瘤小鼠免疫因子MCP-1、ICAM-1表达的影响[J].世界中西医结合杂志,2017,12(1):53-56.
[21] 姚祺,郭辉,陈玲玲,等.桂枝茯苓丸抗大鼠子宫肌瘤作用机制研究[J].世界中医药,2020,15(24):3761-3766.
[22] 杨真,尚玉敏,程凤.桂枝茯苓丸对子宫肌瘤患者血清VEGF、COX-2及HIF-1α表达水平的影响[J].辽宁中医杂志,2021,48(3):95-98.
[23] 许京红.中药血府逐瘀汤辅助治疗对子宫肌瘤患者临床疗效及黄体生成素、雌二醇、卵泡雌激素水平表达的影响[J].中医临床研究,2020,12(5):103-105.
[24] 周立,李淑荣,张娥.血府逐瘀汤对子宫肌瘤模型大鼠NOS、TNF-a、IL-2水平及子宫平滑肌厚度的影响[J].世界中医药,2019,14(6):1408-1411.
[25] 刘笑梅,张蕾,陈桂玲,等.坤泰胶囊对雌激素、孕激素联合诱发子宫肌瘤大鼠激素水平及相关生长因子的影响[J].中医杂志,2017,58(11):960-965.
相似文献/References:
[1]李哲,常暖*,李黎.中药院内制剂政策历史、现状及对策[J].中国中医药图书情报杂志,2014,38(1):38.[doi:10.3969/j.issn.2095-5707.2014.01.012]
Li Zhe,Chang Nuan*,Li Li.The Policy History, Present Situation and Countermeasures of Chinese Medicine Hospital Preparations[J].Chinese Journal of Library and Information Science for Traditional Chinese Medicine,2014,38(4):38.[doi:10.3969/j.issn.2095-5707.2014.01.012]
[2]史磊,曹思思.基于利水功效组群药物的中药药性规律研究[J].中国中医药图书情报杂志,2014,38(4):10.[doi:10.3969/j.issn.2095-5707.2014.04.003]
Shi Lei,Cao Sisi.A Study on Regularity of the Property of Chinese Materia Medica Based on Group Drugs with Diuretic Efficacy[J].Chinese Journal of Library and Information Science for Traditional Chinese Medicine,2014,38(4):10.[doi:10.3969/j.issn.2095-5707.2014.04.003]
[3]林敏华,吴昊,曾华敏,等.中药提取物及有效成分防治非酒精性脂肪性肝病的作用机制研究进展[J].中国中医药图书情报杂志,2020,44(1):72.[doi:10.3969/j.issn.2095-5707.2020.01.017]
LIN Min-hua,WU Hao,ZENG Hua-min,et al.Research Progress in Mechanism of Action of Chinese Materia Medica Extracts and Active Components for Prevention and Treatment of Nonalcoholic Fatty Liver Disease[J].Chinese Journal of Library and Information Science for Traditional Chinese Medicine,2020,44(4):72.[doi:10.3969/j.issn.2095-5707.2020.01.017]
[4]黄凯文,刘芳.岭南医家江勒卿与《药物学注释》[J].中国中医药图书情报杂志,2020,44(4):48.[doi:10.3969/j.issn.2095-5707.2020.04.012]
HUANG Kai-wen,LIU Fang.Lingnan Doctor Jiang Le-qing and Yao Wu Xue Zhu Shi[J].Chinese Journal of Library and Information Science for Traditional Chinese Medicine,2020,44(4):48.[doi:10.3969/j.issn.2095-5707.2020.04.012]
[5]蒋志雄,朱智德*,祁祥,等.中药联合环磷腺苷葡胺治疗病毒性心肌炎的Meta分析[J].中国中医药图书情报杂志,2021,45(5):13.[doi:10.3969/j.issn.2095-5707.2021.05.003]
JIANG Zhi-xiong,ZHU Zhi-de*,QI Xiang,et al.Meta-analysis on Chinese Materia Medica Combined with Meglumine Adenosine Cyclphosphate in the Treatment of Viral Myocarditis[J].Chinese Journal of Library and Information Science for Traditional Chinese Medicine,2021,45(4):13.[doi:10.3969/j.issn.2095-5707.2021.05.003]
[6]支晓娟.粤港澳大湾区中药专利分析与思考[J].中国中医药图书情报杂志,2021,45(6):18.[doi:10.3969/j.issn.2095-5707.2021.06.004]
ZHI Xiao-juan.Analysis and Thinking on Patent of Chinese Materia Medica in Guangdong-Hong Kong-Macao Greater Bay Area[J].Chinese Journal of Library and Information Science for Traditional Chinese Medicine,2021,45(4):18.[doi:10.3969/j.issn.2095-5707.2021.06.004]
备注/Memo
收稿日期：2021-01-30
更新日期/Last Update:
2021-07-15